RxDoctor Payments Data

Demir Baykal, MD

Cardiovascular Disease · Lawrenceville, GANPI 1336158104

Payments from drug & device makers

$25,664in general payments, 2019–2025

Across 317 payments — averaging $80.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$19K
  • Actelion Pharmaceuticals US, Inc.$842
  • Impulse Dynamics (USA) Inc.$764
  • Merck$548
  • Novartis$455
  • Kestra Medical Technology Services, Inc.$452
  • plus $4K from 30 others

What the payments were for

  • Speaking & faculty fees$16,96166%
  • Travel & lodging$1,0884%
  • Food & beverage$7,42729%
  • Education$1881%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,664 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$300,651
Medicare patients
839
Services billed
3,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag42$1,216,509
AdempasRiociguat70$959,230
Orenitram ErTreprostinil Diolamine28$753,008
OpsumitMacitentan46$591,405
EliquisApixaban384$451,325
XareltoRivaroxaban161$211,477
Ambrisentan48$173,430
JardianceEmpagliflozin137$167,967
EntrestoSacubitril/Valsartan99$119,026
Tadalafil36$88,784
FarxigaDapagliflozin Propanediol46$53,489
AdcircaTadalafil14$49,254
OzempicSemaglutide15$22,920
BrilintaTicagrelor26$21,073
Bosentan18$19,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan$842$1,827,688106 claims
BayerAdempas$70$959,23070 claims
PfizerEliquis$263$451,325384 claims
Johnson & JohnsonXarelto$426$211,477161 claims
Boehringer IngelheimJardiance$93$167,967137 claims
NovartisEntresto$455$119,02699 claims
AstraZenecaFarxiga, Brilinta$338$74,56272 claims
United Therapeutics CorporationAdcirca$19,016$49,25414 claims
Novo NordiskOzempic$35$22,92015 claims
Esperion Therapeutics, Inc.Nexletol$14$12,63112 claims
Sanofi-aventis U.S. LLCMultaq$16$12,09211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →